Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

538 ARTÍCULOS , VIENDO DEL 376 AL 390

A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington's disease

Verny C, Bachoud-Lévi AC, Durr A, Goizet C, Azulay JP, Simonin C, Tranchant C, Calvas F, Krystkowiak P, Charles P, Youssov K, Scherer C, Prundean A, Olivier A, Reynier P, Saudou F, Maison P, Allain P, von Studnitz E, Bonneau D; CYST-HD Study Group.

Mov Disord. 2017 Jun;32(6):932-936. doi: 10.1002/mds.27010. Epub 2017 Apr 24.

Cataplexy and Its Mimics: Clinical Recognition and Management

Pillen S, Pizza F, Dhondt K, Scammell TE, Overeem S.

Curr Treat Options Neurol. 2017 Jun;19(6):23. doi: 10.1007/s11940-017-0459-0.

Seventy Years with the Globus Pallidus: Pallidal Surgery for Movement Disorders Between 1947 and 2017

Cif L, Hariz M.

Mov Disord. 2017 Jul;32(7):972-982. doi: 10.1002/mds.27054. Epub 2017 Jun 7.

Functional neuroimaging and chorea: a systematic review

Ehrlich DJ, Walker RH.

J Clin Mov Disord. 2017 Jun 21;4:8. doi: 10.1186/s40734-017-0056-0. eCollection 2017.

Huntington's Disease: Pathogenic Mechanisms and Therapeutic Targets

Wright DJ, Renoir T, Gray LJ, Hannan AJ.

Adv Neurobiol. 2017;15:93-128. doi: 10.1007/978-3-319-57193-5_4.

The therapeutic implication of a novel SCN2A mutation associated early-onset epileptic encephalopathy with Rett-like features

Liang JS, Lin LJ, Yang MT, Wang JS, Lu JF.

Brain Dev. 2017 Nov;39(10):877-881. doi: 10.1016/j.braindev.2017.06.003. Epub 2017 Jul 11.

Valbenazine for Tardive Dyskinesia

Freudenreich O, Remington G.

Clin Schizophr Relat Psychoses. 2017 Summer;11(2):113-119.

Losing ground: Frontostriatal atrophy disrupts language embodiment in Parkinson's and Huntington's disease

Birba A, García-Cordero I, Kozono G, Legaz A, Ibáñez A, Sedeño L, García AM.

Neurosci Biobehav Rev. 2017 Sep;80:673-687. doi: 10.1016/j.neubiorev.2017.07.011. Epub 2017 Aug 2.

Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease

McGarry A, Kieburtz K, Abler V, Grachev ID, Gandhi S, Auinger P, Papapetropoulos S, Hayden M.

J Huntingtons Dis. 2017;6(3):189-199. doi: 10.3233/JHD-170241.

Design optimization for clinical trials in early-stage manifest Huntington's disease

Frost C, Mulick A, Scahill RI, Owen G, Aylward E, Leavitt BR, Durr A, Roos RAC, Borowsky B, Stout JC, Reilmann R, Langbehn DR, Tabrizi SJ, Sampaio C; TRACK-HD Investigators.

Mov Disord. 2017 Nov;32(11):1610-1619. doi: 10.1002/mds.27122. Epub 2017 Sep 14.

Medical management of motor manifestations of Huntington disease

McCusker EA, Loy CT.

Handb Clin Neurol. 2017;144:141-150. doi: 10.1016/B978-0-12-801893-4.00012-2.

The role of rehabilitation therapy in Huntington disease

Quinn L, Busse M.

Handb Clin Neurol. 2017;144:151-165. doi: 10.1016/B978-0-12-801893-4.00013-4.

Preclinical motor manifestations of Huntington disease

McGarry A, Biglan KM.

Handb Clin Neurol. 2017;144:93-98. doi: 10.1016/B978-0-12-801893-4.00007-9.

The Neuropsychology of Huntington's Disease

Snowden JS.

Arch Clin Neuropsychol. 2017 Nov 1;32(7):876-887. doi: 10.1093/arclin/acx086.

Unilateral Thalamic Infarct Presenting as a Convulsive Seizure

Kumar R, Brohi H, Mughul A.

J Coll Physicians Surg Pak. 2017 Sep;27(9):S104-S105.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias